ALPRE

FR0010169920

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 10:25:30 2024-04-30 am EDT			5-day change	1st Jan Change
5.15 ^EUR	+0.98%		+25.61%	-9.65%

2023	Predilife: a project accredited by Finance Innovation	CF
2023	Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Predilife S.A. has filed an IPO in the amount of €7.006296 million.

December 04, 2018 at 12:00 am EST

Predilife S.A. has filed an IPO in the amount of €7.006296 million. Security Name: Shares Security Type: Common Stock Securities Offered: 591,748 PriceRange: €8.76 to €11.84

Latest news about PREDILIFE

Predilife: a project accredited by Finance Innovation	23-09-04	CF
Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-14	CI
Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Predilife: predictive assessment contract with Colas	23-04-12	CF
Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-28	CI
Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-25	CI
Predilife Taps Eurofins to Conduct Genetic Testing of Saliva Samples	21-12-20	MT
Global markets live: Valneva, Glencore, Facebook, Roche, Hertz...	21-10-18
Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-09-28	CI
Global markets live: Valneva,Boeing, Facebook, Kubota, Otis...	21-09-23
Global markets live: Credit Suisse, Apple, Verizon...	21-05-03
Predilife S.A. and Institut Curie Announce Partnership Covering Genetic Analyses for Mammorisk, the Next-Generation Test Predicting the Risk of Breast Cancer	19-05-06	CI
Predilife S.A. has completed an IPO in the amount of €3.591232 million.	18-12-18	CI
Predilife S.A. has filed an IPO in the amount of €7.006296 million.	18-12-04	CI

PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women,over 300,000 French women and 500,000 English.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
PREDILIFE	-9.65%	20.38M
EXACT SCIENCES CORPORATION	-18.88%	10.91B
IOVANCE BIOTHERAPEUTICS, INC.	+53.75%	3.3B
GUARDANT HEALTH, INC.	-32.50%	2.19B
BGI GENOMICS CO., LTD.	-14.31%	2.16B
VERACYTE, INC.	-26.83%	1.5B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+28.55%	1.09B
SEEGENE, INC.	-3.28%	737M
CAREDX, INC	-23.50%	404M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-43.27%	386M

Bio Diagnostics & Testing

PREDILIFE

Equities

ALPRE

FR0010169920

Biotechnology & Medical Research

Predilife S.A. has filed an IPO in the amount of €7.006296 million.

Latest news about PREDILIFE

Chart PREDILIFE

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Bio Diagnostics & Testing